BRILINTA (ticagrelor) Launches “Complete the Course” — a Creative Education Program for Patients With ACS, Including

  BRILINTA (ticagrelor) Launches “Complete the Course” — a Creative Education
  Program for Patients With ACS, Including “Access My BRILINTA” Support
  Service Focused on Continuity of Care

  National Survey Shows Patients with Acute Coronary Syndrome Value Robust,
              Multi-Channel Communication about their Medication

Business Wire

WILMINGTON, Del. -- September 19, 2012

AstraZeneca (NYSE: AZN) today introduced Complete the Course, a creative
education program to support patients taking BRILINTA^® (ticagrelor). Patients
who enroll in the Complete the Course program receive support services across
multiple channels to help them stay on their full course of BRILINTA therapy.
One important support resource now available is Access My BRILINTA, which
provides time-saving prescription access and affordability information to
patients and healthcare providers.

Please read full Prescribing Information, including Boxed WARNINGS, and
Medication Guide. Additional ...

Please read full Prescribing Information, including Boxed WARNINGS, and
Medication Guide. Additional information can be found at
www.brilintatouchpoints.com. (Photo: AstraZeneca)

Complete the Course was created specifically to address patient preference for
how they receive information about their medication as they transition from
hospital to home. A recent nationwide patient survey showed that patients with
ACS value robust, multi-channel communication to learn more about the
medication prescribed. The survey was sponsored by AstraZeneca and conducted
by Ipsos Public Affairs.

“Cardiologists have a tremendous responsibility to not only provide the best
possible care for their patients, but also to ensure that their patients
receive complete information about their diagnosis and the importance of
adherence to treatment,” stated James Ferguson, MD, Executive Director,
Medical Affairs and Strategic Development, and Vice President for Global
Medical Affairs. “With the combination of the BRILINTA Complete the Course
program along with Access My BRILINTA, we are now able to provide a variety of
resources to patients with ACS and healthcare providers to help ensure
continuity and optimal delivery of care throughout the course of treatment.”

A nationwide patient survey was conducted in 201 patients with ACS. The
patients with ACS were adults aged 60 years and older who have suffered a
heart attack or have been diagnosed with ACS (including heart attack and chest
pain), and have been prescribed some form of medication for treatment of their
heart attack.

Key findings from the survey to support more multi-channel methods of
communication indicate that:^*

  *Fifty-nine percent of respondents have never researched the medication
    they were prescribed for the treatment of their heart attack on the
    Internet. While 41 percent of respondents have used the Internet to
    research their medication.
  *Fifty-one percent of respondents indicated they are likely to answer
    phone-call reminders about prescription refills from the prescription drug
    manufacturer, while only 34 percent reported they are likely to read
    emails about their prescription and heart attack treatment from the
    prescription drug manufacturer.
  *Sixty-nine percent of respondents reported they are likely to read the
    inserts that come with their prescription from the pharmacy.

*Based on a survey conducted both online and via telephone among a nationwide
cross-section of 201 U.S. adults aged 60 years and older conducted from
February 29 – March 9, 2012. The survey respondents were 57.2% male. The
percent of responders across age groups was: 51% 60–69 years, 32% 70–79 years,
and 17% 80+ years. The overall margin of error was ± 6.9% points at a 95%
confidence interval.

“With over one million people diagnosed with ACS each year, there is an ever
increasing need for additional tools and resources that can help patients and
their caregivers learn about and understand ACS. These materials may help
patients maintain their medication regimen,” said Dr. Ferguson.

In addition to the right types of communication, the timing is equally
important. Certain moments in time after a cardiovascular event help define a
patient’s continuum of informational needs. These include hospital discharge,
when patients are first Learning about BRILINTA, a couple months later when
Reinforcement is necessary and further down the road when Re-education may be
important. While any patient can choose to receive any offering any time,
Complete the Course will call their attention to those that will be most
applicable based on their course of therapy.

Patients enrolled in Complete the Course will receive information about heart
attacks, preventing a second heart attack, tips on preparing for doctor’s
visits, and reminders about doctor appointments, daily dosing and refills. The
material also outlines the benefits and side effects of therapy with BRILINTA
and why it is important to continue taking medication, as prescribed. The
program includes a patient pull-out tool that illustrates how BRILINTA helps
stop platelets from sticking together and forming a clot in an artery.

Access My BRILINTA provides time-saving prescription access and affordability
support. It will be available online and by telephone. The program will help
ensure patients have access to their therapy with BRILINTA as prescribed,
including benefit verification, copay and coverage information, and
information on prior authorization. This service will be available for
patients, caregivers, physicians, nurses, discharge planners, pharmacists and
other health care providers. Access My BRILINTA is available by calling
1-888-512-7454 (888-51-BRILINTA) or visit BRILINTA.com.

BRILINTA is indicated to reduce the rate of thrombotic cardiovascular (CV)
events in patients with acute coronary syndrome (ACS: unstable angina [UA],
non-ST-elevation myocardial infarction [NSTEMI], or ST-elevation myocardial
infarction [STEMI]). BRILINTA has been shown to reduce the rate of a combined
end point of CV death, myocardial infarction (MI), or stroke compared to
clopidogrel. The difference between treatments was driven by CV death and MI
with no difference in stroke. In patients treated with an artery-opening
procedure known as percutaneous coronary intervention (PCI), BRILINTA reduces
the rate of stent thrombosis.

BRILINTA has been studied in ACS in combination with aspirin. Maintenance
doses of aspirin above 100 mg decreased the effectiveness of BRILINTA. Avoid
maintenance doses of aspirin above 100 mg daily.

IMPORTANT SAFETY INFORMATION ABOUT BRILINTA

WARNING: BLEEDING RISK

  *BRILINTA, like other antiplatelet agents, can cause significant, sometimes
    fatal, bleeding
  *Do not use BRILINTA in patients with active pathological bleeding or a
    history of intracranial hemorrhage
  *Do not start BRILINTA in patients planned to undergo urgent coronary
    artery bypass graft surgery (CABG). When possible, discontinue BRILINTA at
    least 5 days prior to any surgery
  *Suspect bleeding in any patient who is hypotensive and has recently
    undergone coronary angiography, percutaneous coronary intervention (PCI),
    CABG, or other surgical procedures in the setting of BRILINTA
  *If possible, manage bleeding without discontinuing BRILINTA. Stopping
    BRILINTA increases the risk of subsequent cardiovascular events

WARNING: ASPIRIN DOSE AND BRILINTA EFFECTIVENESS

  *Maintenance doses of aspirin above 100 mg reduce the effectiveness of
    BRILINTA and should be avoided. After any initial dose, use with aspirin
    75 mg - 100 mg per day

CONTRAINDICATIONS

BRILINTA is contraindicated in patients with a history of intracranial
hemorrhage and active pathological bleeding such as peptic ulcer or
intracranial hemorrhage. BRILINTA is also contraindicated in patients with
severe hepatic impairment because of a probable increase in exposure; it has
not been studied in these patients. Severe hepatic impairment increases the
risk of bleeding because of reduced synthesis of coagulation proteins

WARNINGS AND PRECAUTIONS

  *Moderate Hepatic Impairment: Consider the risks and benefits of treatment,
    noting the probable increase in exposure to ticagrelor
  *Premature discontinuation increases the risk of MI, stent thrombosis, and
    death
  *Dyspnea was reported in 14% of patients treated with BRILINTA and in 8% of
    patients taking clopidogrel. Dyspnea resulting from BRILINTA is
    self-limiting. Rule out other causes
  *BRILINTA is metabolized by CYP3A4/5. Avoid use with strong CYP3A
    inhibitors and potent CYP3A inducers. Avoid simvastatin and lovastatin
    doses >40 mg
  *Monitor digoxin levels with initiation of, or any change in, BRILINTA
    therapy

ADVERSE REACTIONS

  *The most commonly observed adverse reactions associated with the use of
    BRILINTA vs clopidogrel were Total Major Bleeding (11.6% vs 11.2%) and
    dyspnea (14% vs 8%)
  *In clinical studies, BRILINTA has been shown to increase the occurrence of
    Holter-detected bradyarrhythmias. PLATO excluded patients at increased
    risk of bradycardic events. Consider the risks and benefits of treatment

Please read full Prescribing Information, including Boxed WARNINGS, and
Medication Guide.

You are encouraged to report negative side effects of prescription drugs to
the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For patients that require BRILINTA beyond their hospital stay, a savings card
program is available based on eligibility. Commercially insured and
cash-paying patients may be eligible for one free 30-day prescription and can
save up to $825 per year on their next 11 refills. For each refill (a 30-day
supply of up to 60 tablets), savings may apply after the first $18 spent by a
patient, up to a $75 savings limit. Patients covered through Medicare,
Medicaid or a resident of Massachusetts may be eligible for one month free
prescription. Patients can find out more at www.BRILINTAtouchpoints.com or by
calling 1-888-412-7454.

AstraZeneca also offers a U.S. patient assistance program for BRILINTA through
its AZ&Me^TM Prescription Savings Program. To determine eligibility, patients
can visit www.AZandMe.com or call 1-800-AZandMe (292-6363).

                                   – ENDS –

NOTES TO EDITOR

About BRILINTA^® (ticagrelor) tablets

BRILINTA is an oral antiplatelet treatment for ACS. BRILINTA is a
direct-acting P2Y[12] receptor antagonist in a chemical class called
cyclopentyltriazolopyrimidines (CPTPs). BRILINTA works by inhibiting platelet
activation and has been shown to reduce the rate of thrombotic CV events, such
as a heart attack or CV death, in patients with ACS.

BRILINTA is available in 90-mg tablets to be administered with a single 180-mg
oral loading dose (two 90-mg tablets) followed by a twice daily, 90-mg
maintenance dose. Following an initial loading dose of aspirin, BRILINTA
should be used with a maintenance dose of 75 mg - 100 mg aspirin once daily,
81-mg aspirin dose in the US.

BRILINTA is a registered trademark of the AstraZeneca group of companies.

About Acute Coronary Syndrome (ACS)

ACS is an umbrella term for conditions that result from insufficient blood
supply to the heart muscle. These conditions range from unstable angina (UA),
non–ST-elevation myocardial infarction (NSTEMI), or ST-elevation myocardial
infarction (STEMI).

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a
primary focus on the discovery, development and commercialization of
prescription medicines for gastrointestinal, cardiovascular, neuroscience,
respiratory and inflammation, oncology and infectious disease. AstraZeneca
operates in over 100 countries and its innovative medicines are used by
millions of patients worldwide.

For more information about AstraZeneca in the U.S. or our AZ&Me™ Prescription
Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe
(292-6363).

2004600 9/12

Photos/MultimediaGallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50411534&lang=en

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50411534&lang=en

Contact:

AstraZeneca
Media Inquiries US
Stephanie Jacobson, +1 302-885-5924 mob: +1 302-379-0443
Julia Walker, +1 302-885-5172 mob: +1 610-350-8240
or
Investor Inquiries US
Ed Seage, +1 302-886-4065 mob: +1 302-373-1361
Jorgen Winroth, +1 212-579-0506 mob: +1 917-612-4043